New drug tested for tough liver cancers after other treatments fail
NCT ID NCT00422877
Summary
This study tested a modified version of a chemotherapy drug called Taxoprexin for people with advanced liver, gallbladder, or bile duct cancer that had worsened after their first treatment. The goal was to see if the weekly drug infusions could shrink tumors, control the disease, and extend life. The trial was small and ended early, so its results are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF THE LIVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.